The distinct role of guanine nucleotide exchange factor Vav1 in Bcl-2 transcription and apoptosis inhibition in Jurkat leukemia T cells

Acta Pharmacologica Sinica

Volumn 32, Issue 1, 2011, Pages 99-107

  Yin, Jie ^a   Wan, Ya Juan ^a   Li, Shi Yang ^a   Du, Ming Juan ^a   Zhang, Cui Zhu ^a   Zhou, Xing Long ^a   Cao, You Jia ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

apoptosis; Bcl 2; guanine nucleotide exchange factor; Jurkat T cells; Vav1

Indexed keywords

CASPASE 3; CASPASE 8; FAS LIGAND; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR VAV1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; RAC2 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DNA FRAGMENTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; JURKAT CELLS; LEUKEMIA; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-VAV; RAC GTP-BINDING PROTEINS;

EID: 78651073322     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.185     Document Type: Article

References (42)

1. Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989; 8: 2283-90.
2. Movilla N, Bustelo XR. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol 1999; 19: 7870-85.
3. Schuebel KE, Bustelo XR, Nielsen DA, Song BJ, Barbacid M, Goldman D, et al. Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes. Oncogene 1996; 13: 363-71.
4. Fischer KD, Zmuldzinas A, Gardner S, Barbacid M, Bernstein A, Guidos C. Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes. Nature 1995; 374: 474-7.
5. Turner M, Mee PJ, Walters AE, Quinn ME, Mellor AL, Zamoyska R, et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 1997; 7: 451-60.
6. Fujikawa K, Miletic AV, Alt FW, Faccio R, Brown T, Hoog J, et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med 2003; 198: 1595-608.
7. Cao Y, Janssen EM, Duncan AW, Altman A, Billadeau DD, Abraham RT. Pleiotropic defects in TCR signaling in a Vav-1-null Jurkat T-cell line. EMBO J 2002; 21: 4809-19.
8. Paccani SR, Boncristiano M, Patrussi L, Ulivieri C, Wack A, Valensin S, et al. Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects. Blood 2005; 106: 626-34.
9. Prieto-Sanchez RM, Hernandez JA, Garcia JL, Gutierrez NC, San MJ, Bustelo XR, et al. Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. Br J Haematol 2006; 133: 642-5.
10. Hornstein I, Pikarsky E, Groysman M, Amir G, Peylan-Ramu N, Katzav S. The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. J Pathol 2003; 199: 526-33.
11. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005; 7: 39-49.
12. Bartolome RA, Molina-Ortiz I, Samaniego R, Sanchez-Mateos P, Bustelo XR, Teixido J. Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res 2006; 66: 248-58.
13. Zugaza JL, Lopez-Lago MA, Caloca MJ, Dosil M, Movilla N, Bustelo XR. Structural determinants for the biological activity of Vav proteins. J Biol Chem 2002; 277: 45377-92.
14. Tybulewicz VL, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol 2009; 9: 630-44.
15. Fischer KD, Kong YY, Nishina H, Tedford K, Marengere LE, Kozieradzki I, et al. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr Biol 1998; 8: 554-62.
16. Katzav S. Vav1: An oncogene that regulates specific transcriptional activation of T cells. Blood 2004; 103: 2443-51.
17. Zhou Z, Yin J, Dou Z, Tang J, Zhang C, Cao Y. The calponin homology domain of Vav1 associates with calmodulin and is prerequisite to T cell antigen receptor-induced calcium release in Jurkat T lymphocytes. J Biol Chem 2007; 282: 23737-44.
18. Blanchet F, Cardona A, Letimier FA, Hershfield MS, Acuto O. CD28 costimulatory signal induces protein arginine methylation in T cells. J Exp Med 2005; 202: 371-7.
19. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002; 109: S97-107.
20. Kong YY, Fischer KD, Bachmann MF, Mariathasan S, Kozieradzki I, Nghiem MP, et al. Vav regulates peptide-specific apoptosis in thymocytes. J Exp Med 1998; 188: 2099-111.
21. Ramaswamy M, Dumont C, Cruz AC, Muppidi JR, Gomez TS, Billadeau DD, et al. Cutting edge: Rac GTPases sensitize activated T cells to die via Fas. J Immunol 2007; 179: 6384-8.
22. Tuosto L, Marinari B, Piccolella E. CD4-Lck through TCR and in the absence of Vav exchange factor induces Bax increase and mitochondrial damage. J Immunol 2002; 168: 6106-12.
23. Vigorito E, Gambardella L, Colucci F, McAdam S, Turner M. Vav proteins regulate peripheral B-cell survival. Blood 2005; 106: 2391-8.
24. Opalinska JB, Machalinski B, Ratajczak J, Ratajczak MZ, Gewirtz AM. Multigene targeting with antisense oligodeoxynucleotides: An exploratory study using primary human leukemia cells. Clin Cancer Res 2005; 11: 4948-54.
25. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176: 640-51.
26. Katzav S. Flesh and blood: The story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Lett 2007; 255: 241-54.
27. Koncz G, Kerekes K, Chakrabandhu K, Hueber AO. Regulating Vav1 phosphorylation by the SHP-1 tyrosine phosphatase is a fine-tuning mechanism for the negative regulation of DISC formation and Fasmediated cell death signaling. Cell Death Differ 2008; 15: 494-503.
28. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-87.
29. Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, et al. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 2002; 16: 759-67.
30. Heckman CA, Mehew JW, Boxer LM. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002; 21: 3898-908.
31. Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene 2001; 20: 6372-81.
32. Tybulewicz VL. Vav-family proteins in T-cell signalling. Curr Opin Immunol 2005; 17: 267-74.
33. Aghazadeh B, Lowry WE, Huang XY, Rosen MK. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 2000; 102: 625-33.
34. Yu H, Leitenberg D, Li B, Flavell RA. Deficiency of small GTPase Rac2 affects T cell activation. J Exp Med 2001; 194: 915-26.
35. Miletic AV, Graham DB, Sakata-Sogawa K, Hiroshima M, Hamann MJ, Cemerski S, et al. Vav links the T cell antigen receptor to the actin cytoskeleton and T cell activation independently of intrinsic Guanine nucleotide exchange activity. PLoS One 2009; 4: E6599.
36. Yang FC, Kapur R, King AJ, Tao W, Kim C, Borneo J, et al. Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 2000; 12: 557-68.
37. Romero F, Dargemont C, Pozo F, Reeves WH, Camonis J, Gisselbrecht S, et al. p95vav associates with the nuclear protein Ku-70. Mol Cell Biol 1996; 16: 37-44.
38. Hobert O, Jallal B, Schlessinger J, Ullrich A. Novel signaling pathway suggested by SH3 domain-mediated p95vav/heterogeneous ribonucleoprotein K interaction. J Biol Chem 1994; 269: 20225-8.
39. Romero F, Germani A, Puvion E, Camonis J, Varin-Blank N, Gisselbrecht S, et al. Vav binding to heterogeneous nuclear ribonucleoprotein (hnRNP) C. Evidence for Vav-hnRNP interactions in an RNA-dependent manner. J Biol Chem 1998; 273: 5923-31.
40. Houlard M, Romero-Portillo F, Germani A, Depaux A, Regnier-Ricard F, Gisselbrecht S, et al. Characterization of VIK-1: A new Vav-interacting Kruppel-like protein. Oncogene 2005; 24: 28-38.
41. Houlard M, Arudchandran R, Regnier-Ricard F, Germani A, Gisselbrecht S, Blank U, et al. Vav1 is a component of transcriptionally active complexes. J Exp Med 2002; 195: 1115-27.
42. Hofmann TG, Hehner SP, Droge W, Schmitz ML. Caspase-dependent cleavage and inactivation of the Vav1 proto-oncogene product during apoptosis prevents IL-2 transcription. Oncogene 2000; 19: 1153-63.